Clinical trial · Interventional
IDEntification of New Predisposition Genes in Differentiated THYroid Cancer
NCT05014698CI-TRIAL-00101837IDENTHY-KterminatedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): end-of-study visit not completed within the protocol timeframe
Summary
Brief summary (as posted)
The purpose of this research is to find new predisposition genes for differentiated thyroid cancer (DTC).
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Differentiated Thyroid Cancer | Thyroid Gland Papillary Carcinoma | PROBABILISTIC | 0.70 |
| Thyroid Cancer, Nonmedullary | Malignant Thyroid Gland Neoplasm | CURATED_EXACT | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| WGS | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- WGS
- description
- at inclusion visit : \- Blood collection for whole Genome sequencing will be performed At final visit : the results of the WGS will be delivered to patients
- interventionNames
- Genetic: WGS
Primary outcomes (1)
- measure
- Type and Number of genetic variants associated with or causing the development of differentiated thyroid cancer
- timeFrame
- within 2 years
- description
- To be achieved by a whole genome sequencing (WGS) approach in a familial analysis of patients with differentiated thyroid cancer. In addition, high-throughput genotyping of multiple individuals in each family will allow complementary detection of genomic regions that are shared only by affected subjects
Secondary outcomes (2)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 8 Years
Show eligibility criteria text
Inclusion Criteria: * Probant subjects * Minor or adult subject * Adult subject or legal guardian for minor subjects agreeing to sign the study consent and biospecimen consent * Subject with differentiated thyroid cancer without an identified causative mutation in the BAP1 and DICER 1 predisposition genes * Patient affiliated to a valid social security plan Relative subjects * Adult subjects * Subject agreeing to sign the study consent and the biocollection consent * Subject with differentiated thyroid cancer or from a family with several cases of differentiated thyroid cancer without a causal mutation identified in the BAP1 and DICER 1 predisposition genes * Patient affiliated to a social security plan Exclusion Criteria: * Subject refusing to participate * Subjects with a causal mutation identified in the predisposition genes: BAP1 and DICER 1 * Subjects under guardianship, curatorship or safeguard of justice or not socially insured * Subjects with another syndromic predisposition to thyroid cancer (Cowden, Werner, PAF)
References
Publications (0)
Data not yet available
No reference posted for this study.